UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,678	01/24/2006	Hiroshi Nakamura	284303US0PCT	2912
22850 7590 07/12/2007 OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET			EXAMINER	
			MORRIS, PATRICIA L	
ALEXANDRIA, VA 22314			ART UNIT	PAPER NUMBER
			1625	
				·
			NOTIFICATION DATE	DELIVERY MODE
			07/12/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

	Application No.	Applicant(s)				
	10/565,678	NAKAMURA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Patricia L. Morris	1625				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUN 136(a). In no event, however, may a will apply and will expire SIX (6) MO e, cause the application to become A	ICATION. reply be timely filed NTHS from the mailing date of this communication. NBANDONED (35 U.S.C. § 133).				
Status		·				
1) Responsive to communication(s) filed on 30 A	Responsive to communication(s) filed on <u>30 April 2007</u> .					
2a)⊠ This action is FINAL . 2b)☐ This	This action is FINAL . 2b) This action is non-final.					
, ,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ⊠ Claim(s) 1,3-8 and 11-23 is/are pending in the 4a) Of the above claim(s) 4-6 and 8 is/are with 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1,7,12-14,19-21 and 23 is/are rejected 7) ⊠ Claim(s) 3,10,11,15-18 and 22 is/are objected 8) □ Claim(s) are subject to restriction and/or	idrawn from consideration ed. I to.					
Application Papers						
9) The specification is objected to by the Examina 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct of the oath or declaration is objected to by the Examination.	cepted or b) objected to drawing(s) be held in abeyaction is required if the drawin	ance. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)						
1) Notice of References Cited (PTO-892)		Summary (PTO-413) o(s)/Mail Date				
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date		Informal Patent Application				

DETAILED ACTION

Claims 1,3, 7, 9 and 10-23 are under consideration in this application.

Claims 4-6 and 8 remain held withdrawn from consideration as being drawn to nonelected subject matter. 37 CFR 1.142(b).

Election/Restrictions

The requirement is still deemed sound and proper and is therefore made FINAL.

Again, this application has been examined to the extent readable on the elected compounds wherein R_b represents (optionally substituted) pyridyl and A and R_c as set forth in claim 1, exclusively. Applicants have now added additional heterocycles, i.e., N-loweralkylpiperadino (assumed to be piperidino) which were not originally claimed. Applicants have already received an examination on the merits. Hence, the piperidino compounds are drawn to nonelected subject matter.

Applicants request rejoinder of all the process claims. However, rejoinder cannot be offered at this time because applicants have failed to present any claims directed to the **allowable elected compounds. The claims do not meet the requirements of 35 USC 112.** Applicants were given the opportunity to amend the claims to overcome the rejections under 35 USC 112 and they have failed to do so.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process

invention to be rejoined. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is *presented prior* to final rejection or allowance, whichever is earlier. Applicants are reminded that <u>Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.</u>

Page 3

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be **allowable**, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b).

Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. urther, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

The rejections under 35 USC 102 and 103 are hereby withdrawn in view of applicants' amendments to claims.

Claim Rejections - 35 USC > 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1,7 and 12-14 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Again, the expression substituted is employed with considerable abandon throughout claims 1, 7 and 12-14 with no indication given as to what the subsituents or any group which can removed by acid really are.

One should be able, from a reading of the claims, determine what that claim does or does not encompass.

Why? Because that claim precludes others from making, using, or selling that compound for 20 years. Therefore, one must know what compound is being claimed.

The specification lacks direction or guidance for placing all of the alleged products in the possession of the public without inviting more than routine experimentation. Applicants are referred to In re Fouche, 169 USPQ 429 CCPA 1971, MPEP 716.02(b).

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is undue. These factors include 1) the breadth of the claims, 2) the nature of the invention, 3) the state of the prior art, 4) the level of one of ordinary

skill, 5) the level of predictability in the art, 6) the amount of direction provided by the inventor, 7) the existence of working examples, and 8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

The nature of the invention

The nature of the invention is the preparation of compounds.

State of the Prior Art

Substituents and other unknown groups for R_c can have very different properties. Substituents etc., tend to convert from less stable to more stable forms. No method exists to predict what substituent will work with any significant certainty. Compounds can convert from one form to another during the manufacturing process of a pharmaceutical drug and will change the pharmacological affects of the drug. This is why it is important to monitor the compounds during manufacture of the drug to see if it persists during manufacture.

The amount of direction or guidance and the presence or absence of working examples

The specification fails to describe any substituents. Subsituents often change into other forms during drug manufacture. Based on the unpredictability in the art, applicants are not entitled to any and all unknown substituents.

The written description is considered inadequate here in the specification. Conception of the intended substituents and forms should not be the role of the reader. Applicants should, in return for a 20 year monopoly, be disclosing to the public that which they know as an actual demonstrated fact. The disclosure should not be merely an invitation to experiment. This is a 35

USC 112, first paragraph. If you (the public) find that it works, I claim it, is not a proper basis of patentability. In re Kirk, 153 USPQ 48, at page 53.

Page 6

The breadth of the claims

The breadth of the claims are drawn to all unknown substituted compounds in addition to the instant compounds.

The quantity of experimentation needed

The quantity of experimentation needed would be undue when faced with the lack of direction and guidance present in the instant specification in regards to the compounds and their unknown other forms being claimed.

In terms of the 8 Wands factors, undue experimentation would be required to make or use the invention based on the content of the disclosure due to the breadth of the claims, the level of unpredictability in the art of the invention, and the poor amount of direction provided by applicants. Taking the above factors into consideration, it is not seen where the instant other forms are enabled by the instant application.

Genentech Inc v. Novo Nordisk A/S (CAFC) 42 USPQ2d 1001, states that "a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion" and [p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable".

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 10/565,678

Art Unit: 1625

Claims 1, 7, 12-14, 19-21 and 23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Again, the expression substituted in claims 1, 7, and 12-14 is indefinite.

Applicants merely assert that the term is clear.

Contra to applicants' arguments in the instant, one cannot tell from a simple reading of the compound. Then one must, by preparing the compound himself, determine if the substituent works or not. Where is the specific claiming and distinctly pointing out? How can applicants regard as their invention inexact concepts? The breadth of is finite.

Applicants are claiming a compound of the formula. Pure chemistry, a compound. Not a resin of general property ranges, but a pure compound. That compound used for any purpose is taken from the public in a 20-year monopoly to applicants. Then, the public is entitled to know what compound they cannot use. Yet, the claim is not specific to that compound. The public cannot tell what they may not use. How is a claim of the instant breadth defensible in an infringement action?

As applied to pure compounds, In re Cavallito and Gray, 134 USPQ 370, and In re Sus and Schaefer, 134 USPQ 301, are considered to set the proper applicable standard of required definiteness and support.

Again, Claim 7 fails to clearly claim what is intended by applicants since it fails to recite the reagents and reaction conditions such as solvents, temperature, etc. What is the nitrilization agent? Nitrilization is an obvious process under 35 U.S.C. 103.

The term comprising in claim 19 is open-ended and allows for the inclusion of other variables not contemplated by applicants.

Claims 20, 21 and 23 lack antecedent basis because R_y can only represent p-alkoxybenzyl, diphenylmethyl or (substituted)alkyl.. Moreover, R_y cannot represent alkoxy.

The claims measure the invention. <u>United Carbon Co. v, Binney & Smith.</u>, 55 USPQ 381 at 384, col. 1, end of 1st paragraph, Supreme Court of the United States (1942).

The U.S. Court of Claims held to this standard in Lockheed Aircraft Corp. v. United States, 193 USPQ 449, "Claims measure invention and resolution of invention must be based on what is claimed".

The C.C.P.A. in 1978 held "that invention is the subject matter defined by the claims submitted by the applicant. We have consistently held that no applicant should have limitations of the specification read into a claim where no express statement of the limitation is included in the claim": In re Priest, 199 USPQ 11, at 15.

Allowable Subject Matter

Claims 3, 10,11,15-18 and 22 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and if rewritten directed solely to the elected compounds.

Conclusion

Claims 1, 7, 12-14,19-21 and 23 are not allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia L. Morris whose telephone number is (571) 272-0688. The examiner can normally be reached on Mondays through Fridays.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (told-free)

> Primary Examiner Art Unit 1625

plm

July 3, 2007